Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Phase 2 Recruiting
70 enrolled
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Phase 2 Recruiting
60 enrolled
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Phase 2 Recruiting
100 enrolled
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Phase 2 Recruiting
12 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Phase 2 Recruiting
48 enrolled
MK-6482-015
Phase 2 Recruiting
322 enrolled 3 FDA
DeLLight
Phase 2 Recruiting
60 enrolled
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase 2 Recruiting
200 enrolled
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Phase 2 Recruiting
130 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
SUR-CAN
Phase 2 Recruiting
88 enrolled
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Phase 2 Recruiting
29 enrolled
Fezo-ADT
Phase 2 Recruiting
60 enrolled
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Phase 2 Recruiting
66 enrolled
A Study of Pasireotide in People With Prolactinoma
Phase 2 Recruiting
10 enrolled
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Phase 2 Recruiting
90 enrolled
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Phase 2 Recruiting
740 enrolled
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Phase 2 Recruiting
70 enrolled
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Phase 2 Recruiting
21 enrolled
TENET
Phase 2 Recruiting
20 enrolled
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Phase 2 Recruiting
86 enrolled
ReLUTH
Phase 2 Recruiting
146 enrolled
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Phase 2 Recruiting
21 enrolled
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Phase 2 Recruiting
96 enrolled
18FDOPA HI
Phase 2 Recruiting
100 enrolled
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Phase 2 Recruiting
32 enrolled
CapTemY90
Phase 2 Recruiting
70 enrolled
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Phase 2 Recruiting
111 enrolled
Pan-MSI-ACSE
Phase 2 Recruiting
120 enrolled
IMMUNORARE5
Phase 2 Recruiting
154 enrolled
INTERVAL
Phase 2 Recruiting
31 enrolled
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Phase 2 Recruiting
30 enrolled
FOLFIRINEC
Phase 2 Recruiting
218 enrolled
BELIEVE-VHL
Phase 2 Recruiting
100 enrolled
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Phase 2 Recruiting
20 enrolled
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Phase 2 Recruiting
60 enrolled
Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 Recruiting
400 enrolled
STOPNET
Phase 2 Recruiting
78 enrolled
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Phase 2 Recruiting
500 enrolled
NEONEC
Phase 2 Recruiting
78 enrolled
LUTARTERIAL
Phase 2 Recruiting
23 enrolled
LUMOD-ID
Phase 2 Recruiting
120 enrolled
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Phase 2 Recruiting
240 enrolled
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Phase 2 Recruiting
20 enrolled
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 Recruiting
33 enrolled
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Phase 2 Recruiting
28 enrolled
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Phase 2 Recruiting
600 enrolled
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Phase 2 Recruiting
18 enrolled